 This study evaluated the impact of specialty pharmacist integration on time to insurance approval for Pimovansarin, a Parkinson disease-related psychosis treatment approved by the FDA. The results showed that median time to approval decreased post-integration and that the specialty pharmacist performed valuable monitoring and interventions. This article was authored by Sabrina Livesey, PharmD, CSP, Nisha Bisha, PharmD, Robert McCormick, PharmD, and others.